30 June 2014

Fragments vs Dengue virus helicase and methyltransferase

Dengue fever is a disease whose nastiness is hinted at by its common name, “breakbone fever”. The eponymous virus relies on two viral proteins, a helicase (Hel) and a methyltransferase (MTase), for replication. In a recent paper in Antiviral Research, Karine Barral and coworkers at Aix-Marseille Université use fragment-based methods to tackle both of these proteins.

The researchers used the 500 compound Maybridge fragment library (2009 edition) and performed a biophysical cascade, starting with a thermal shift assay at 2 mM of each fragment. Hits were defined as fragments that stabilized the protein by at least 0.5 °C; there were 36 hits against Hel and 32 against MTase, with 6 in common.

Both Hel and MTase are amenable to crystallography, so the hits against each protein were soaked into crystals. Unfortunately, none of these yielded structures for Hel. Critics of thermal shift assays could argue that this is yet another example of false positives, a possibility the researchers consider. That said, 11 of the fragments inhibited Hel by at least 25% in biochemical assays (at 2 mM fragment), though none inhibited greater than 50%.

The results against MTase were more salubrious: 7 fragments produced structures, for a success rate of 22%. Interestingly, these fragments bound to 4 distinct sites on the protein. Two different enzymatic assays were used to test all the fragment hits, and many of them showed activity in one or both. A few fragments – including 5 of those characterized crystallographically – were sufficiently active that IC50 values could be determined, though these were mostly millimolar.

My one quibble is that the authors state that “to our knowledge, only one example of random FBS has been conducted on an RNA virus target.” This ignores some beautiful work from both Roche and Astex on Hepatitis C, another virus that carries its genome as RNA. Still, it is fair to say that fragments could play a larger role in tackling infectious diseases.

At the last CHI FBDD conference, Rod Hubbard noted that, as more academics enter the fragment field, we will see more publications describing fragment hits against tough targets. The next steps – taking a fragment to a nascent lead – are often harder to resource in an academic environment. Still, it’s good to see these initial studies. At the very least, they go some way to addressing the question of whether the targets are ligandable.

26 June 2014

Who's Reviewing this Crap?

Dan and I teach a short course on FBDD; next chance to catch a version in October.  My favorite part of Dan's section is when he goes off on PAINS and the continuing pollution of the literature.  Rhodanines in particular get Dan's dander up.  I often come off as anti-academic because many of their "drug discovery" papers are crap.  Or they claim something is a lead without it being one.   I think it is time to start PAINS shaming these papers.  For those of you not intimately familiar with "shaming" it is very popular with dog shaming.  Well, here is our first PAINS Shaming.  This paper (pointed out by Matt Netherton at B-I, thanks Matt!) unabashedly points out the offensive molecule as a rhodanine. In the article, they point out:
What is particularly interesting about the most active species investigated here is that it has a structure that is very similar to that found in the drug epalrestat, an aldolase reductase inhibitor that is used to treat diabetic neuropathy, and is approved for clinical use in Japan, China, and India. This is encouraging because rhodanines as a class are known to often have activity in widely different assays, and indeed computer programs such as PAINS categorize, [our compounds] (as well as epalrestat) as possible “pan assayinterference compounds”. This can mean that the compounds cause false positives in assays, or that they may be multitarget inhibitors. In some cases multitargeting may be undesirable; however, in the context of anti-infective development, multitargeting is expected to increase efficacy as well as decrease the possibility of resistance development, both very desirable features.
  I am sorry, but this is exactly the Underpants Gnomes business plan. All I can say after reading this is who's reviewing this crap and saying it is all right?

23 June 2014

Metric poll results: plus ça change…

Of all the topics on Practical Fragments, none have generated as much Sturm und Drang as ligand efficiency (LE) and related metrics. But how are researchers actually using these? The results of our latest poll are in, and it appears that ligand efficiency is still widely used.
Lipophilic ligand efficiency (LLE or LipE) has made significant strides in the past 3 years, but despite the proliferation of other metrics none of them have really caught on. (Note that we didn’t ask about enthalpic efficiency or SILE in 2011.)

So at least for now – and while fully acknowledging that all metrics are simplifications – I think we can conclude that most readers of this blog find LE and LLE both useful and sufficient for their needs.

(Full technical disclosure: the 2011 poll was run in Blogger, but the polling feature is buggy and has a tendency to lose votes. This poll was run using Polldaddy, but unfortunately the free version does not reveal how many individuals voted. Since respondents could choose more than one metric, the number of voters is impossible to determine from the results. I tried to account for this upfront by including a “Please Click this Box” to tally individuals, but only 77 people did so, less than the 91 people who voted for LE. I thus had to guess at the total number of respondents. The most conservative choice was to add 91 (the largest single category) to the 8 respondents who use no metrics, giving 99 independent voters. Obviously this might overstate the apparent percentage of people who use any given metric, but as 86% of respondents used LE in 2011 the effect is probably small.)

18 June 2014

Fragment Events in 2014 and 2015 - midyear update

The year is nearly half over, but there are still some great events ahead, and 2015 is already shaping up nicely!


July 19-22: Zing conferences is holding its first-ever Fragment Based Drug Discovery in Punta Cana, Dominican Republic. In addition to the amazing location there are more than two dozen great speakers, so definitely check this one out - there is still time to register by June 30.

August 10-14: The 248th ACS National Meeting will be held in the cool gray city of San Francisco, and there will be several presentations on fragments as well as what I believe will be the first session on PAINS.  

September 21-24: FBLD 2014 will be held in Basel, Switzerland. This marks the fifth in an illustrious series of conferences organized by scientists for scientists, the last of which was in San Francisco in 2012.  I believe this will also be the first major dedicated fragment conference in continental Europe. You can read impressions of FBLD 2010 and FBLD 2009. Also, if you're new to the field (or looking for a refresher) Rod Hubbard, Ben Davis, and I will teach an introductory workshop on Sunday, September 21.

October 8-10: CHI's 12th Annual Discovery on Target takes place in Boston, where it looks like there will be several talks relevant to readers of this blog. And on October 7, Teddy and I will be teaching a short course on targeting protein-protein interactions, which naturally includes fragments.


February 17-18: Newly added! SELECTBIO is holding its Discovery Chemistry Congress in Berlin, Germany, with a number of talks on fragment-based lead discovery.

March 22-24: The Royal Society of Chemistry will be holding Fragments 2015 in Cambridge, UK, the fifth in the series organized by RSC-BMCS. You can read impressions of Fragments 2013.

April 21-23: CHI’s Tenth Annual Fragment-Based Drug Discovery will be held in San Diego. You can read impressions of this year's meeting here and here, last year's meeting here and here, the 2012 meeting here, the 2011 meeting here, and 2010 here. As this will be their ten-year anniversary, I think they're planning something big!

June 9-12: NovAliX will hold its second conference on Biophysics in Drug Discovery in Strasbourg, France. Though not exclusively devoted to FBLD, there is lots of overlap; see here, here, and here for discussions of last year's event.

December 15-20: Finally, the first ever Pacifichem Symposium devoted to fragments will be held in Honolulu, Hawaii. The Pacifichem conferences are held every 5 years and are designed to bring together scientists from Pacific Rim countries including Australia, Canada, China, Japan, Korea, New Zealand, and the US. There is lots of activity in these countries, and since travel to mainland US and Europe is onerous this should be a great opportunity to meet many new folks - in Hawaii no less! Abstract submissions will open in January.

Know of anything else? Add it to the comments or let us know!

16 June 2014

Irreversible fragments

Last year we highlighted a paper in which fragments were attached to a “warhead,” a chemical group that could form a reversible covalent bond with cysteine residues in proteins. These fragments were then screened against a kinase to identify nanomolar inhibitors. In a new paper in J. Med. Chem., Alexander Statsyuk and coworkers at Northwestern University describe a similar approach using irreversible fragments. (See here for In the Pipeline’s take.)

As we noted last year, one of the nice things about using reversible warheads is the fact that you can run experiments under thermodynamically-controlled conditions. Indeed, this was the idea behind Tethering (here and here), in which a library of disulfide-containing fragments is allowed to equilibrate with a cysteine-containing protein; if a fragment has inherent affinity for the protein, the disulfide bond will be stabilized towards reduction and can be identified using mass spectrometry. (Full disclosure: I am an inventor of Tethering, and my company, Carmot Therapeutics, Inc., has an exclusive license to the intellectual property covering this and other technologies.)

Irreversible warheads operate at least partly under kinetic, rather than thermodynamic, control. For example, if all the fragments are extremely reactive, the protein will react with whichever fragment it happens to encounter first, regardless of whether the fragment has any inherent affinity for the protein.

Acrylamide moieties are able to form irreversible bonds to cysteine residues and are even starting to be found in drugs. In 2012, researchers at Imperial College London tested an acrylamide-containing analog of one of the (disulfide) hits from the original Tethering paper. This successfully labeled the target protein thymidylate synthase (TS), while several other acrylamide-containing molecules did not, and the fragment was selective for TS over two other enzymes with active-site cysteine residues.

Regardless of whether your warhead is reversible or not, it is important that different members of the library have similar reactivities: if the inherent reactivities of the fragments are different, it will be difficult to distinguish inherent binding energies from chemical reactivities. One of the problems with acrylamides is that subtle changes in chemical structures can have dramatic effects on intrinsic reactivities. The new paper compares rate constants of two acrylamides reacting with a low molecular-weight thiol, and finds that one reacts 2,000-fold faster than the other. The researchers tested three other classes of electrophiles – vinylsulfonamides, aminomethyl methyl acrylates, and methyl vinylsulfones – and found that these had narrower ranges of reactivity. They chose acrylates and built a set of 100 acrylate-modified fragments. Happily, when 50 of these were tested for reactivity, there was only a 2.4-fold difference between the most reactive and the least reactive members.

These 100 fragments were tested in pools of ten against the classic cysteine protease papain using mass spectrometry, and three hits were identified. Enzymatic assays revealed that these three hits were also irreversible inhibitors of the protein with respectable activities (kinact/Ki = 0.46-1.2 M-1s-1), while a member of the library that did not label in the mass spectrometry assay was a weaker inhibitor (kinact/Ki = 0.037 M-1s-1). Moreover, the papain hits did not label three other enzymes containing active-site cysteines, though these enzymes could be modified with other fragments in the library.

In the case of Tethering, the disulfide linker was a means for finding fragments; when these fragments were developed further, the disulfide linker was replaced. However, given the renewed interest in covalent drugs, some warheads might be able to be retained. It will be fun to see how these types of strategies develop.

11 June 2014

Liberte, egalite, fraternite! with Lemonade

Ligand efficiency has a long and glorious history in FBDD, discussed in depth.  Most recently, it was the subject of a LONG discussion.  Since its inception, FBDD has tried to fit in, be like the cool kids as it were.  "Regular" medchem had the Rule of 5, so Astex gave us the Rule of 3, aka the Voldemort Rule.  The principles of FBDD just make sense, but overturning entrenched dogma is hard.  So, simple metrics were devised to explain to people why smaller is better.  Groups tried to create better and more predictive metrics.  Well, we can add lipophilicity, or log D, or make it empirical.  The more complicated, obviously the better it is.  The search for a GUM (Grand Unifying Metric) is ongoing.  

Then Schultz had to come along and assault the Bastille.  So, to the walls Men!  Defend the King! And so he was, but there was no peace.  But trouble was brewing and now another assault has come.  Peter Kenny and his compatriots have taken another shot at the King, with the completely unprovocative title: "Ligand Efficiency Metrics Considered Harmful".  The paper reviews current LEMs (Ligand Efficiency Metrics), and proposes a better approach.  As Pete has said at length, one of his major problems is with the choice of arbitrary assumptions of standard state, as he laid out in this comment.  Of course, the real issue is the intercept and what that means.

What are the key problems the authors point out?
  • Correlation Inflation
  • Defining assumptions are arbitrary
  • Scaling (dividing measured activity by physicochemical property) and offsetting (subtracting physicochemical property from measured activity) are used but no one has ever said why you do one or the other for a given LEM
  • Scaling assumes a linear relationship between activity and property (zero intercept)
  • Offsetting implies the LEM has a unit slope
  • LEMs are not quantitative, but are presented as such.
  • Units matter!  ΔG = RTln(Kd/C) where C= concentration of standard state.  Substitution of IC50 in this equation is easy to do, but not at all correct.  A more subtle example of the problem is provided by the definition of LLEAT as the sum of a (dimensionless) number and a quantity with units of molar energy per heavy atom.[Click to embiggen.]
 So, this is a fun paper to read.  I highly recommend it.  The authors go into exquisite detail of what each and EVERY factor that goes into a LEM means and how it is used, and more importantly how it SHOULD be used.  The first conclusion is that there is no basis in science for any of the assumptions related to scaling or offsetting.  They recommend that data be modeled to determine a trend.  They argue that only in this way can a given compound be determined to have beaten the trend.  The King is dead; long live the King?

They are right, of course, and IMNSHO it doesn't matter.  I still aver that ligand efficiency metrics are useful.  I can measure accurately with a meter stick that is only 95 cm, as long as I know it is 95cm.  The same thing with any LEM; understand its limitations and use it appropriately.  And remember, its a guide, not a hard and fast rule. 

Pete and colleagues set up the obvious acronym, LEMONS (Ligand Efficiency Metrics of No Substance).  And when life gives you LEMONS, you make LEMONADE (Ligand Efficiency Metrics with No Additional Determinate Evaluation). 

09 June 2014

Fluorinated Fragments vs G-quadruplexes

Recently we highlighted an example of fragment-based ligand discovery against a riboswitch. Of course, RNA can form all kinds of interesting structures, and in a new paper in ACS Chem. Biol. Ramón Campos-Olivas (Spanish National Cancer Research Centre) and Carlos González (CSIC, Madrid) and their collaborators describe finding fragments that bind G-quadruplexes.

G-quadruplexes, as their name suggests, consist of groups of four guanine residues hydrogen bonding to one another in a planar arrangement. These individual tetrads then stack on top of one another. They can form in guanine-rich regions of RNA or DNA. Most famously, G-quadruplexes are found in telomeres at the ends of chromosomes. However, they are also found in telomeric repeat-containing RNA (TERRA), and are required for cancer cells to proliferate indefinitely.

The researchers used 19F-NMR screening to identify fragments that bound to an RNA containing 16 (UUAGGG) repeats (TERRA16). 19F-NMR is a technique about which Teddy waxes rhapsodic, and in this incarnation involves examining the NMR spectra of fragments in the presence or absence of TERRA16. Fragments that bind to the RNA show changes in 19F spin relaxation, resulting in broader, lower intensity signals. The library consisted of 355 compounds from a variety of sources, and although most of them were fragment-sized, a couple dozen had molecular weights above 350 Da.

The initial screen produced a fairly high hit rate (20 fragments), of which seven were studied in detail. Standard proton-based STD NMR confirmed the 19F-NMR results. The researchers then turned to a shorter RNA containing only two repeats (TERRA2); this RNA sequence dimerizes to form a G-quadruplex. All seven fragments stabilized this complex against thermal denaturation, consistent with binding. Six of the fragments also induced changes to the 1H NMR spectrum of TERRA2, though one also caused general line broadening that could indicate aggregation. For the well-behaved fragments, dissociation constants (KD) were determined by measuring changes in chemical shifts with increasing concentrations of ligand. KD values ranged from 120 to 1900 micromolar, with modest ligand efficiencies ranging from 0.17-0.28 kcal/mol/atom.

Of course, selectivity against other nucleic acid structures is a major concern, so the researchers used 1H and 19F NMR to assess compound binding to a tRNA, a DNA duplex, and a DNA analog of TERRA2 also able to form a G-quadruplex. Aside from the putative aggregator, none of the seven compounds bound tRNA, and only two (including the aggregator) bound duplex DNA. However, all the compounds bound to the DNA G-quadruplex. Interestingly though, the DNA sequence used can form two types of G-quadruplexes in solution (parallel or antiparallel), whereas the equivalent RNA can only form a parallel dimer. In all cases the small molecules appeared to shift the equilibrium of the DNA to the parallel conformation, consistent with their initial identification as RNA binders.

Last year we highlighted another paper in which fragments were identified that may bind to a different DNA G-quadruplex. It would be interesting to functionally compare these two sets of hits. For example, do the hits identified initially against the DNA G-quadruplex also bind RNA G-quadruplexes? Of course, as with the riboswitch effort, there is a long way to go. It should be an interesting journey.

04 June 2014

Fragments vs riboswitches

Most of fragment-based lead discovery – indeed, most of lead discovery – is directed against proteins. However, RNA is also an essential biomolecule, and in a new paper in Chem. Biol. Adrian R. Ferré-D’Amaré and colleagues at the National Heart, Lung, and Blood Institute, along with collaborators at the University of Cambridge and the University of North Carolina Chapel Hill, demonstrate that fragments can potentially make an impact here as well. This is the first example I know of where crystallography has been used to assess fragment hits against RNA molecules.

The story begins several years ago, when Chris Abell and colleagues became interested in the TPP riboswitch thiM. This is a bacterial stretch of RNA that binds to the essential cofactor thiamine pyrophosphate (TPP). This binding causes a change in conformation that regulates protein translation; small molecules that interfere with this process could lead to new antibiotics. In 2010 the researchers described a fragment screen using equilibrium dialysis, in which the RNA was added to one chamber along with radiolabeled thiamine, which binds with low micromolar affinity. This chamber was separated from another chamber containing fragments by a dialysis membrane permeable to small molecules and fragments but not to (larger) RNA. Fragments were screened in pools of five, and pools that caused displacement of radioligand were then deconvoluted to identify the active fragments. A total of 20 fragment binders were identified out of roughly 1300 tested.

WaterLOGSY NMR was used to confirm the binding of these 20 fragments to the riboswitch, and all of them were then tested using isothermal titration calorimetry, which yielded dissociation constants for 17 of them ranging between 22 and 670 micromolar. When tested against a different riboswitch, 10 of them appeared to be selective for thiM. The chemical structures of all of these were reported in 2011, along with some speculation as to how they might bind.

Of course, speculation is just that, and in fact fragment hits have been identified against RNA and DNA before. In the new paper the researchers use X-ray crystallography to actually determine the structures of several fragments bound to the riboswitch. This provides several interesting observations.

First, despite the different chemical structures of the fragment hits, all four of those whose structures were determined bind in the same region where the pyrimidine moiety of the natural ligand TPP binds. In fact, fragment 1 (magenta), which is essentially a fragment of TPP (green), almost perfectly superimposes on the corresponding moiety of TPP.
More strikingly, the co-crystal structures of each of the fragments bound to the riboswitch reveal that one of the guanosine residues (magenta stick in figure above) rearranges to fill the pocket that would otherwise be occupied by the pyrophosphate moiety of TPP (orange and red above). This occurs with fragment 1 as well as other fragments that do not resemble the natural ligand.

The researchers also took the useful step of solving the crystal structure of thiamine (cyan) bound to thiM. Since thiamine is intermediate in size between TPP and fragment 1, you might expect the structure to resemble one or the other, but as it turns out it binds in yet a third mode in which the pyrimidine ring no longer superimposes with the other two structures, nor does the guanosine residue rearrange to fill the pyrophosphate-binding pocket. This provides an interesting example of fragmenting natural products (TPP to thiamine to fragment 1). Although all of the molecules bind with high ligand efficiencies, it is unlikely that their binding modes could have been accurately predicted.

As the researchers note, the conformational shifts observed with these fragments could lead to antibiotics that selectively target an inactive form of the riboswitch. Although they’ve got a long way to go, it is fun to see folks applying FBLD to non-traditional targets.

02 June 2014

Is that a Forest over there? The place with all the trees...

Sometimes, in the FBHG arena, we get deep into the weeds.  I am a simple man, with a simple understanding of FBHG.  There are a few tenets that I hold dear: Small, not very complex molecules have less of a chance of bad interactions.  You need high sensitivity (read:biophysical) methods to detect them robustly.  Libraries don't need to be bigger than a few thousand.  Now, this last one can be/has been/will be a subject of much debate.  There is no way to cover ALL of available chemical space and still run a screen in this lifetime.  However, I think most people agree that you can sample an "adequate" (that term being highly fungible) amount of available chemical space with a few thousand compounds.  Heck, if you have the resources to screen 10,000s of fragments, go right ahead.  

But, what molecules should be in your fragment collection?  To paraphrase Justice Brandeis, you know a good fragment when you see it.  I think every body could have the same 2000 or so fragments and each find their own success.  However, we are lucky that there are a metric boatload of commercial vendors of fragments, so we won't have to.  In this paper, the authors aim to determine what is currently available in commercial fragment space (emolecules) that covers known medchem space.  They use CHEMBL as the source of "medchem" space and analyzed the distribution of biologically active molecules and discovered property trends that differentiate active from inactive.  Here are there results: 
In their discussion, they state:
While many typical fragment libraries contain commercial fragments that mostly conform to the Ro3 physicochemical properties criteria, the chemical space these fragments represents may not entirely project to the leadlike and drug-like chemical space that are relevant to medicinal chemistry.
They realize that the overlap between fragment space and CHEMBL-medchem space do not overlap well.  In fact, almost half of the bioactive-derived substructures are not covered by commercially available fragments.  They propose that fragment libraries should focus on those structures represented by bioactive CHEMBL compounds.  They make some suggestions to expand fragment libraries, e.g. polar fragments that are not similar to commercial fragments and more 3D-arity.  However, there is a paucity of these molecules commercially available, so they suggest synthetic focus should be placed here.  

[Ed: Link to paper fixed.  Sorry about that.]